Last reviewed · How we verify

NCT03966313: HemostVAD

Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation

Terminated Last updated 25 March 2025
What this trial tests

trial testing ventricular assist device implantation in End-stage Heart Failure in 26 participants. Terminated before completion.

Timeline
21 June 2019
Primary endpoint
13 April 2024
13 April 2024

Quick facts

Lead sponsorUniversity Hospital, Strasbourg, France
StatusTerminated
Study typeOBSERVATIONAL
Enrollment26
Start date21 June 2019
Primary completion13 April 2024
Estimated completion13 April 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Strasbourg, France

Who can join

18 and older, any sex, with End-stage Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Implanting a ventricular assist device (VAD) is a promising therapy for end-stage cardiac failure. However, the implantation of these devices is associated with a high risk of severe hemorrhages and massive blood product transfusion in the first 48 hours following the implantation. The primary purpose of this study is to assess the functionality of the von Willebrand Factor (vWF) which is essential for hemostasis. The hypothesis is that the high shear stress generated by these VAD expose ADAMTS13 cleaving site on the vWF. This result in a loss of high molecular weight vWF and an acquired von Willebrand syndrome. The secondary purpose of the protocol is to assess platelet function after the implantation of VAD. Indeed, platelet function might be affected shortly after the implantation of the device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for End-stage Heart Failure

Currently open trials in the same condition.

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing